Results 191 to 200 of about 8,440,114 (317)

Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms. [PDF]

Leukemia
Bartalucci N, Tarantino D, Enderti A, Colazzo D, Guglielmelli P, Vannucchi AM.   +5 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Chronic maxillary sinusitis masquerading as a maxillary sinus neoplasm: A case report. [PDF]

Exp Ther Med
Oh JH, Kim SG, Kim SY.
europepmc   +1 more source

Iatrogenic Alterations of Immunologic Surveillance in Man and Their Influence on Malignancy [PDF]

, 1971
Agosin M., Albert D., Alford T. C, Allison A. C, Alpert E., Alpert M. E., Anigsten L., Bach F. H., Baserga R., Bekkum D. W., Berman C., Bortin M. M., Bremberg S., Burnet F. M., Burnet F. M., Burnet F. M., Burnet F. M., Casey T. P., Davis R. C., Dent P. B., Deodhar S. D., Doak P. B., Doll R., Epstein R. B., Fisher E. R., Foley E. J., Foley E. J., Fortner J. G., Grant G. A., Gustafson E. G., Hellman K., Hirsch M. S., Huber J., Immunology and Cancer, Isojima S., Jensen C O., Kay S., Law L. W., MacLean L. D., Mandel M.A., Marchioro T. L., Martin D. C, Martinez C, Mathe G., Mathe G., McIntosh D. A., McKhann C. F., Miller J. F. A. P., Moore G. E., Muizniks H. W., Page A. R., Penn I., Penn I., Penn I., Penn I., Prehn R. T., Pritzker K. P. H., Rabbat A. G., Santos G. W., Santos G. W., Schwartz R., Simmons R. L., Sjogren H. O., Snell G. D., Southam C. M., Speck B., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Tallent M. B., Thomas L., Toolan H.W., Tunner W. S., Tyler A., Vredevoe D. L., Weiler E., Wilson R. E., Zukoski C. F., Zukoski C. F.   +85 more
core   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

C-Cell Carcinoma in a Common Marmoset (Callithrix jacchus) With a Brief Review of Thyroid Neoplasms in Neotropical Primates. [PDF]

J Med Primatol
de Macêdo IL, Gottdenker NL, Oliveira LJ, de Sousa DER, da Fonseca YNG, Cerqueira LA, Borges BP, de Castro MB.   +7 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. [PDF]

J Immunother Cancer
Pesini C, Gil-Bellido M, S Millan L, Oñate C, Calvo-Pérez A, Santiago L, Iglesias E, Bernal JP, Araujo-Voces M, Paz Artigas L, García-Martínez L, Roig FJ, Movilla Meno N, Garcia-Aznar JM, Menéndez-Jandula B, Olave MT, Azaceta Reinares G, Garrote M, Alvarez-Larrán A, Gálvez EM, Sánchez Martínez D, Arias MA, Pardo J, Ramirez-Labrada A.   +23 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms

Frontiers in Oncology
Giuseppe Gaetano Loscocco, Barbara Mora, Naseema Gangat   +2 more
doaj   +1 more source